Barinthus Biotherapeutics (BRNS) Other Non-Current Assets (2021 - 2026)
Barinthus Biotherapeutics (BRNS) reported Other Non-Current Assets of $914000.0 for Q1 2026, up 1.33% on a YoY basis from $902000.0 in Q1 2025, and down 1.72% quarter-over-quarter from $930000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Barinthus Biotherapeutics has reported Other Non-Current Assets for 6 years, with the latest figure at $914000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 1.33% year-over-year to $914000.0; the trailing twelve-month figure through Mar 2026 stood at $914000.0 (up 1.33% YoY), and the FY2025 full-year result was $930000.0, up 5.56% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $914000.0, down from $930000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $1.1 million in Q3 2023, with the low at $138000.0 in Q3 2025.
- Historically, Other Non-Current Assets has averaged $844647.1 across 5 years, with a median of $902000.0 in 2022.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets surged 30.46% — and 2025, when it tumbled 85.1%.
- Barinthus Biotherapeutics' Other Non-Current Assets stood at $976000.0 in 2022, then declined by 9.63% to $882000.0 in 2023, then dropped by 0.11% to $881000.0 in 2024, then grew by 5.56% to $930000.0 in 2025, then fell by 1.72% to $914000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $914000.0 (Q1 2026), $930000.0 (Q4 2025), and $138000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Barinthus Biotherapeutics | 27.08 Mn | -40.03 Mn | - | 914,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 914,000.00 |
| Dec 31, 2025 | 930,000.00 |
| Sep 30, 2025 | 138,000.00 |
| Jun 30, 2025 | 413,000.00 |
| Mar 31, 2025 | 902,000.00 |
| Dec 31, 2024 | 881,000.00 |
| Sep 30, 2024 | 926,000.00 |
| Jun 30, 2024 | 886,000.00 |
| Mar 31, 2024 | 885,000.00 |
| Dec 31, 2023 | 882,000.00 |
| Sep 30, 2023 | 1.06 Mn |
| Jun 30, 2023 | 1.01 Mn |
| Mar 31, 2023 | 1.03 Mn |
| Dec 31, 2022 | 976,000.00 |
| Sep 30, 2022 | 847,000.00 |
| Jun 30, 2022 | 902,000.00 |
| Mar 31, 2022 | 788,000.00 |
| Dec 31, 2021 | 804,000.00 |
| Sep 30, 2021 | 719,000.00 |